Open an account

Moleculin Biotech

MBRX · NASDAQ

$6.19+$5.93 (+2235.85%)TodayMarket closed ·
Prev close $0.265

MBRX analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 5 analysts

Average $12.24 (+97.7% upside)

Low
$2.02
Now
$6.19
High
$32.55

Upgrades and downgrades

The latest rating actions, newest first

MBRX analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 28, 2026MaintainsBuy
HC Wainwright & Co.Mar 24, 2026MaintainsBuy
HC Wainwright & Co.Dec 11, 2025MaintainsBuy

The case for and against

Updated Feb 9, 2026

Bull case

Moleculin Biotech Inc. is experiencing positive momentum in its Annamycin program, as recent findings demonstrate a favorable cardiotoxicity profile and highlight the drug's potential to address resistant tumors, particularly in acute myeloid leukemia (AML). The Phase 3 MIRACLE study is gathering pace, with a notable increase in enrollment suggesting strong interest from investigators and underscoring a significant unmet need in relapsed/refractory AML. This growing enthusiasm among clinical partners, coupled with a strategic global expansion of study sites, positions Moleculin Biotech favorably for potential future success in the market.

Bear case

Moleculin Biotech's financial projections exhibit a conservative outlook, particularly concerning the anticipated year-over-year market penetration and the annual costs associated with Annamycin. This conservatism suggests potential challenges in achieving growth expectations and managing operational costs effectively. Consequently, the overall financial health of the company may be negatively impacted, leading to a lack of confidence in its market performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.